Navigation Links
Takeda's Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
Date:5/22/2008

SAN FRANCISCO, May 22 /PRNewswire/ -- Takeda San Francisco Inc. announced today the appointment of Mary Haak-Frendscho, Ph.D., as president and chief scientific officer. Dr. Haak-Frendscho will be responsible for leading all activities at Takeda San Francisco including overall research and preclinical development, process development studies and operations for antibody therapeutics.

Takeda San Francisco is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited of Osaka, Japan ("Takeda").

"Dr. Haak-Frendscho's strong leadership skills and biotechnology experience will greatly contribute to the success of Takeda San Francisco," said Shigenori Ohkawa, Ph.D., general manager, pharmaceutical research division, Takeda. "Takeda San Francisco will play an increasingly critical role in the expansion of Takeda's R&D capabilities as we look to promote the development of antibody therapeutics, and I am confident that Dr. Haak-Frendscho will help us realize our goals in the antibody field."

With more than 17 years of pharmaceutical and biotechnology experience, Dr. Haak-Frendscho has held positions at Genentech, Abgenix and most recently, at XOMA, where she served as chief science officer and vice president, preclinical research and development.

"I feel honored to join Takeda San Francisco," said Dr. Haak-Frendscho. "My background in biotechnology coupled with Takeda San Francisco's impressive existing antibody research is a natural fit, and will help realize Takeda's plan of creating new drugs through in-house R&D activities. I look forward to working with Takeda San Francisco's talented team to develop products that will improve the lives of patients."

Dr. Haak-Frendscho conducted post-doctorate work at the department of immunology, Genentech Inc., in preclinical in vitro and in vivo research and development of a humanized mAb therapeutic product candidate MaE11/MaE25 (Xolair(R)). She holds a doctorate in immunology from th
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product
2. ARIUS presents new findings for anti-cancer antibody programs at AACR
3. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
4. Antibody Engineering Company F-Star Buys Back Royalty Obligations
5. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
6. Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
7. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
8. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
9. ESBATechs Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops
10. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
11. Vaccinex Antibody Licensed to GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
(Date:7/10/2014)... help in the fight against terrorism with the creation ... explosives with the use of light and special glass ... Actuators B: Chemical , the researchers describe a novel ... as low as 6.3 ppm (parts per million). It ... , "Traditionally explosives detection has involved looking for metals ...
(Date:7/10/2014)... basis of psychiatric disorders has been extremely challenging because ... but are insufficient to cause disease. Now investigators reporting ... journal Cell Stem Cell describe a strategy ... interact with other risk factors or environmental exposures to ... pinpoints a genetic variant that may predispose individuals to ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2
... Medivation, Inc.,(Nasdaq: MDVN ) today announced the ... regulatory and quality, Mohammad Hirmand, M.D., to vice,president, ... translational medicine., "As we enter Phase 3 ... the team to lead and advance our clinical ...
... Biosciences, Inc. (Nasdaq: MGRM ) today announced ... of Vice President, Research and,Development, Oncology. Dr. Parry ... programs, including the further,development of Monogram,s proprietary VeraTag(TM) ... platform - the HERMark(TM) Breast Cancer,Assay., Dr. ...
... with Canadian Division of Global Pharmaceutical,Company, ... BASKING RIDGE, N.J., March 24 /PRNewswire/ ... Millennium Biotechnologies Group, Inc.,(OTCBB: MBTG) announced today ... distribution agreement for Resurgex(R), its nutritional formula,for ...
Cached Biology Technology:Medivation Announces Senior Management Promotions 2Medivation Announces Senior Management Promotions 3Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology 2Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology 3Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology 4Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals 2Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals 3
(Date:7/11/2014)... receptor type 1 can inhibit voltage-gated calcium ... neurotransmitter release. However, some scholars demonstrated that ... Ca2+ influx and increase neurotransmitter release. Dr. ... Affiliated to Tongji Medical College, Huazhong University ... cell voltage-clamp and calcium imaging in cultured ...
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
(Date:7/10/2014)...  Pomerantz LLP has filed a class action ... "Company")(NYSE-MKT: PVCT) and certain of its officers.  The ... Middle District of Tennessee , ... consisting of all persons or entities who purchased ... 2013 and May 22, 2014, both dates inclusive ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... When battling an epidemic of a deadly parasite, less resistance ... A freshwater zooplankton species known as ... parasite that can infect more than 60 percent of the ... evolves quickly, balancing infection resistance and reproduction. A new ...
... 2012. Metformin, a drug widely used to treat Type II ... the University of Maryland Marlene and Stewart Greenebaum Cancer Center ... Research . Primary liver cancer, or hepatocellular carcinoma, is an ... and is the fastest-growing cause of cancer-related deaths among American ...
... March 30, 2012 The Phoenix Community Alliance (PCA) ... Genomics Research Institute (TGen), with its most prestigious award. ... City Starr Award for his work in improving the ... studying diseases such as Alzheimer,s, diabetes and many types ...
Cached Biology News:Weakness can be an advantage in surviving deadly parasites, a new study shows 2Weakness can be an advantage in surviving deadly parasites, a new study shows 3Commonly used diabetes drug may help to prevent primary liver cancer 2Commonly used diabetes drug may help to prevent primary liver cancer 3Phoenix Community Alliance honors TGen's Dr. Jeffrey Trent 2
... Affinity Life Sciences can provide custom microplate coating using ... washes a variety of plate formats. We can also accommodate ... volume range of 0.5-320 L):, , ... 96 well microplate, ...
... The Bio-Plex maintenance, calibration, and ... custom 96-well plate used for ... calibration procedures using the Bio-Plex ... plate is for use with ...
... sequencing of plasmids and PCR amplicons. ... high performance sequencing pipeline which processes ... day. The key benefits we offer ... rapid turnaround, high sequencing pass rates ...
GLP-compliant, CLIA-certified DNA sequencing service. ASQ and SQA certified quality assurance staff. Auditors welcome....
Biology Products: